Pharmaceutical News and Articles
Comprehensive and up-to-date drug news for both consumers and healthcare professionals.
SGLT2i Use Linked to Lower Risk for Neurodegenerative Disease in T2DM
WEDNESDAY, Sept. 18, 2024 -- For patients with type 2 diabetes, sodium-glucose cotransporter 2 inhibitor (SGLT2i) use is associated with reduced risks for...
Greater Adherence to MIND Diet Linked to Reduced Cognitive Impairment
WEDNESDAY, Sept. 18, 2024 -- Greater Mediterranean-Dietary Approaches to Stop Hypertension Intervention for Neurodegenerative Delay (MIND) diet adherence is...
FDA Approves Ebglyss for Moderate-to-Severe Atopic Dermatitis
WEDNESDAY, Sept. 18, 2024 -- The U.S. Food and Drug Administration has approved Ebglyss (lebrikizumab-lbkz) for adults and children aged 12 years and older...
Trends in Prehospital Encounters for Youth Opioid Overdose Identified
WEDNESDAY, Sept. 18, 2024 -- Prehospital encounters for youth opioid overdoses increased before the COVID-19 pandemic, then increased with onset, and then...
Long-Term Outcomes Good for Face Transplant Recipients, Study Finds
WEDNESDAY, Sept. 18, 2024 -- There have been 50 face transplants performed in 11 countries since the surgery was pioneered back in 2005, and long-term outcomes...
Acute Myocardial Infarction Up in People With Epilepsy, 2008 to 2017
WEDNESDAY, Sept. 18, 2024 -- The prevalence of acute myocardial infarction (AMI) in people with epilepsy increased from 2008 to 2017, according to a study...
Buildup of Metals in Body Can Worsen Heart Disease
WEDNESDAY, Sept. 18, 2024 -- Cadmium, uranium, cobalt: These and other metals found in the environment can collect in the body and exacerbate heart disease...
FDA Expands Use of Breast Cancer Drug Kisqali
WEDNESDAY, Sept. 18, 2024 -- Women with early stage breast cancer may now take Kisquali, a medication already approved for advanced disease, following the U.S...
Feeling Content Helps Shield You From Heart Attack, Stroke
WEDNESDAY, Sept. 18, 2024 -- Folks who are content with what they’ve got could be less likely to suffer a heart attack or stroke, a new study...
Some People With MS May Need Earlier, Higher-Dose Meds
WEDNESDAY, Sept. 18, 2024 -- Early, aggressive treatment of brain lesions caused by multiple sclerosis could help ward off faster decline in patients, a new...
FDA Approves Ocrevus Zunovo (ocrelizumab & hyaluronidase-ocsq) Twice-A-Year Subcutaneous Injection for People With Relapsing and Progressive Multiple Sclerosis
South San Francisco, CA -- September 13, 2024 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the United States...
Tremfya (guselkumab) Receives U.S. FDA Approval for Adults with Moderately to Severely Active Ulcerative Colitis
HORSHAM, Pa. (September 11, 2024) – Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has approved...
FDA Approves Ebglyss (lebrikizumab-lbkz) for the Treatment of Atopic Dermatitis
INDIANAPOLIS, Sept. 13, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today the U.S. Food and Drug Administration (FDA) approved Ebglyss...
FDA Approves Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy
South San Francisco, CA -- September 12, 2024 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and...
Travere Therapeutics Announces Full FDA Approval of Filspari (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy
SAN DIEGO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the U.S. Food and Drug Administration (FDA) has...
KalVista Announces FDA Acceptance of New Drug Application for Sebetralstat for Oral On-Demand Treatment of Hereditary Angioedema
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--Sep. 3, 2024-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the U.S. Food...
Unicycive Therapeutics Announces Submission of the New Drug Application (NDA) to the U.S. FDA for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
LOS ALTOS, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies...
Johnson & Johnson Seeks First Approval of Nipocalimab to Treat Broadest Population Living with Antibody Positive Generalized Myasthenia Gravis
Spring House, Pa. (August 29, 2024) – Johnson & Johnson today announced the submission of a Biologics License Application (BLA) to the U.S. Food and...
Telix Submits NDA for TLX101-CDx (Pixclara) Brain Cancer Imaging Agent
MELBOURNE, Australia, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has submitted a New...
FDA Grants Priority Review to SpringWorks Therapeutics’ New Drug Application for Mirdametinib for the Treatment of Adults and Children with NF1-PN
STAMFORD, Conn., Aug. 28, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on...
Ascletis Enters the Obesity Drug Space with Announcement of Two Ongoing U.S. Phase I Clinical Trials Utilizing Its Small Molecule GLP-1R Agonist ASC30
HONG KONG, Sept. 17, 2024. Ascletis Pharma Inc. ("Ascletis") announces today completion of initial dosing in its two recently initiated U.S. Phase I clinical...
Trishula Therapeutics Presents Positive Results from Phase 1 Trial of TTX-030 in First-Line Metastatic Pancreatic Cancer Patients
SOUTH SAN FRANCISCO, Calif., Sept. 16, 2024. Trishula Therapeutics, Inc., a clinical stage, privately held biotechnology company, today reported final results...
Vico Therapeutics Announces Positive Interim Phase 1/2a Clinical Data of VO659 in Treatment of Huntington's Disease
LEIDEN, Netherlands, Sept. 13, 2024. Vico Therapeutics B.V., a clinical-stage genetic medicines company developing therapies for severe neurological diseases...
Neurocrine Biosciences Provides Update on ERUDITE Phase 2 Data for Luvadaxistat in Adults with Cognitive Impairment Associated with Schizophrenia
SAN DIEGO, Sept. 12, 2024. Neurocrine Biosciences, Inc. today announced that its ERUDITE Phase 2 clinical study of investigational compound luvadaxistat...
Biolexis Unveils Promising Data with an Oral Weight Loss Drug: BLX-7006 Shows Significant Results in Preclinical Studies
LEHI, Utah., Sept. 12, 2024. Biolexis Therapeutics, a biopharmaceutical company pioneering next-generation weight loss treatments, today announced the...
Browse by news type
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Clinical Trial Results
- Generic Drug Approvals
- Drug Shortages
Drugs.com Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
Disclaimer
This library contains syndicated news articles. These articles have not been peer-reviewed by Drugs.com, and therefore we cannot guarantee accuracy to the highest ethical standards. Do further research as needed. Consultation with your physician is essential.